Ong Erin S, Thompson John T
Department of Ophthalmology and Visual Sciences, University of Maryland Baltimore, Baltimore, MD, USA.
Retina Specialists, Greater Baltimore Medical Center, Towson, MD, USA.
J Vitreoretin Dis. 2020 Mar 12;4(3):233-235. doi: 10.1177/2474126420910587. eCollection 2020 Jun.
This report discusses a case of cytomegalovirus (CMV) retinitis in a patient taking tocilizumab for maintenance and remission of giant cell arteritis (GCA).
A case report is presented.
A 78-year-old African American woman with no significant past medical history and an ocular history of primary open-angle glaucoma presented to the retina clinic with vitritis in the right eye. Four months earlier, she had been diagnosed with biopsy-proven GCA and prescribed 30 mg of prednisone daily and 162 mg tocilizumab subcutaneously weekly. Diagnostic vitrectomy with polymerase chain reaction of the vitreous was positive for CMV. Her retinitis gradually resolved after 3 months of treatment with valganciclovir, with no recurrence 4 months after discontinuing the valganciclovir.
Physicians should be aware of the potential to develop CMV retinitis in the setting of tocilizumab use for GCA treatment.
本报告讨论了一例在使用托珠单抗维持和缓解巨细胞动脉炎（GCA）的患者中发生的巨细胞病毒（CMV）视网膜炎病例。
呈现一例病例报告。
一名78岁的非裔美国女性，既往无重大病史，有原发性开角型青光眼的眼部病史，因右眼玻璃体炎就诊于视网膜诊所。四个月前，她被诊断为经活检证实的GCA，并被处方每日服用30毫克泼尼松和每周皮下注射162毫克托珠单抗。玻璃体聚合酶链反应诊断性玻璃体切除术显示CMV阳性。在使用缬更昔洛韦治疗3个月后，她的视网膜炎逐渐消退，停用缬更昔洛韦4个月后未复发。
医生应意识到在使用托珠单抗治疗GCA的情况下发生CMV视网膜炎的可能性。
